Hypoglycaemic and anti-hyperglycaemic activity of Tabernanthe iboga aqueous extract in fructose-fed streptozotocin type 2 diabetic rats

Keyphrases

• Antihyperglycemic 100%
• Tabernanthe Iboga 100%
• Type 2 Diabetic Rats 100%
• Streptozotocin 100%
• Aqueous Extract 100%
• Fructose 100%
• Type 2 Diabetes Mellitus (T2DM) 71%
• Glucose Tolerance 42%
• Diabetes Rats 42%
• Insulin Tolerance 28%
• Polydipsia 28%
• Reduced Body 28%
• Aspartate Transaminase 14%
• Body Weight Gain 14%
• Hypoglycemia Activity 14%
• Hemoglobin A1c (HbA1c) 14%
• Gabon 14%
• Streptozotocin Model 14%
• Central Africa 14%
• Wistar Rats 14%
• Non-fasting Blood Glucose 14%
• Healthy Rats 14%
• Diabetes Complications 14%
• Root Bark 14%
• Glibenclamide 14%
• Blood Glucose 14%
• Hyperglycemia 14%
• Creatinine 14%
• Elevated Triglycerides 14%
• West African 14%
• Alanine Aminotransferase 14%
• Alkaline Phosphatase 14%
• Clinical Management 14%
• Type 2 Diabetes Complications 14%
• Diabetic 14%
• Once-daily 14%
• Type 2 Diabetic 14%
• Liver 14%
• African Region 14%
• Traditional Medicine 14%
• Marker Enzymes 14%
• No Toxicity 14%
• Hypoglycemic Activity 14%

Pharmacology, Toxicology and Pharmaceutical Science

• Ibogaine 100%
• Antidiabetic Agent 100%
• Fructose 100%
• Streptozotocin 100%
• Non Insulin Dependent Diabetes Mellitus 75%
• Polydipsia 25%
• Diabetic Complication 25%
• Alanine Aminotransferase 12%
• Alkaline Phosphatase 12%
• Diabetes Mellitus 12%
• Wistar Rat 12%
• Triacylglycerol 12%
• Aspartate Aminotransferase 12%
• Hyperglycemia 12%
• Creatinine 12%
• Rat Model 12%
• Hemoglobin A1c 12%
• Glibenclamide 12%
• Hypoglycemia 12%